뉴스

Dark web contacts, fluent English: How a gang of four duped US citizens

Dark web contacts, fluent English: How a gang of four duped US citizens

Indicators cited as ‘missing’ being monitored through national surveys, databases: Government sources

The objective is to ensure that each indicator is reported through the most appropriate and authoritative source, reducing duplication and improving overall data coherence, say Union Health Ministry sources

Bank loses Rs 87 lakh to SIM swap fraud, HC orders BSNL to pay over Rs 55 lakh compensation

Karnataka High Court holds BSNL responsible for an Rs 87 lakh bank fraud, stating the telecom giant's negligence in issuing a duplicate SIM enabled cybercriminals. The court dismissed BSNL's challenge, enhancing compensation to over Rs 50 lakh plus interest, emphasizing a heightened duty of care for financial institutions.

Cybercriminals posing as HMWSSB officials dupe residents through fake meter update messages

₹2,004-crore homebuyer fraud: ED arrests 4 promoters for duping over 19,000 buyers

₹2,004-crore homebuyer fraud: ED arrests 4 promoters for duping over 19,000 buyers

NH-544G: ₹5,378-crore Bengaluru-Vijayawada corridor to cut 110 km and up to 4 hours off the journey

The corridor links NH-44 and NH-16, runs through five districts and opens direct access to the Hindupuram and Kopparthi industrial nodes

Bearish move or buying opportunity? Geojit's Anand James on Nifty levels and top stocks to watch

Market volatility took center stage following a sharp late-Friday sell-off triggered by MSCI rebalancing and global cues. While cautious sentiment prevails, Anand James, Chief Market Strategist at Geojit Financial Services, highlights critical Nifty support levels that could prevent further damage. In this exclusive interview, he breaks down the June series rollover data, IT sector resilience, and top stock picks.Edited excerpts from a chat:The sell-off seen in the last 30 minutes on Friday has scared traders as to what could be in the offing on Monday morning. What do you think?IMD’s below-normal monsoon forecast and uncertainty over US-Iran talks in the backdrop gave an ominous feel to the drop that unfolded towards Friday’s close. However, the steepness of the fall is apparently due to MSCI rebalancing, with futures and options segment appearing reluctant to match such move. Nevertheless the large red candle registered on Nifty’s chart needs to be acknowledged, and we will start the new week on a cautious note. That 23500 was defended, gives us reason to be optimistic, but slippage past the same, or inability to reclaim the 10 day SMA near 23750 will confirm bearishness calling for 22800.Nifty has been seeing profit booking at higher levels in last few weeks. What does the rollover data indicate for the June series?The rollover data for June series suggests a cautious to mildly negative undertone despite selective strength. Nifty’s rollover dropped to 69.98% in May, below the 3-month average of 73.05%, indicating reduced willingness to carry forward positions, likely reflecting profit booking at higher levels. Similarly, Bank Nifty rollover moderation points to some cooling in conviction within the heavyweight banking segment.Market breadth has weakened as well, with only 52% of stocks closing positive vs 91% in April, highlighting broader profit-taking pressure. While strong rollovers in select sectors like Oil & Gas, Metals, Power and Infra signal pockets of resilience, weakness in Pharma, Healthcare, and Transportation suggests lack of uniform participation.Although long buildup was visible in Telecom, Capital Goods, and Pharma, the early trend in June appears cautious. Importantly, banks-despite prior long build-up-have started the June series on a weak footing, with heavyweights like SBI and HDFC Bank under pressure, which could weigh on Nifty due to their high index weight.Nifty IT is showing signs of resilience even during sell-off. What are the charts indicating at?The Nifty IT index is showing early signs of a trend reversal after a prolonged corrective phase. On the daily chart, the formation of an inverted head and shoulders pattern suggests a base-building process, with prices currently hovering near the neckline zone around the 29,500-29,600 region. A sustained move above this level could confirm a breakout and trigger momentum towards higher resistances.On the higher timeframe, the weekly MACD is on the verge of a bullish crossover, indicating a potential shift from bearish to positive momentum. This aligns with improving price structure and supports the medium-term recovery thesis.From a longer-term perspective, the monthly candlestick is forming a pin bar Doji, typically seen near inflection points, highlighting rejection of lower levels around the 27,000-28,000 zone and signaling demand absorption.However, confirmation is key. Immediate support lies near 28,000, while a decisive breakout above the neckline could open upside towards 31,000-32,000. Failure to sustain above key resistance may keep the index range bound.HFCL was among the top gainers of the week. Do you see signs of the momentum continuing in the week ahead?Long wicked candle on Friday, with a close above upper bollinger band point to a mix of strong trending nature and emerging cautiousness. Oscillators appear reluctant, but are yet to confirm an impending collapse. With these in the backdrop, longs may be held on to, but ideally with a stop loss placed near 168.Natco Pharma fell 14% on Friday after weak Q4 results. Do you see signs of bottom-fishing emerging in the coming week?Yes. The single day red candle which has resulted in a break of structure, is likely to be followed by bottom fishing and a pull back rally that could extend 3-4%. However, we do not see enough signs to indicate that such pull back attempt could sustain.Give us your top ideas of the week. INDIANB (LTP: 833)View: BuyTarget: 930SL: 790 Indian Bank continues to maintain a structurally strong uptrend on the weekly chart, characterised by a series of higher highs and higher lows since early 2024. The recent profit booking since April seems to have found a support near 800 healthy consolidation after a sharp rally, with the stock holding firmly above the 780-750 support zone, which now acts as a strong demand base.Despite the recent pullback from near 1000 levels, the correction appears time-wise rather than price-destructive, suggesting profit booking rather than trend reversal. The presence of a rising support trendline reinforces the bullish structure.Momentum indicators are cooling off from overbought levels, which is constructive in a trending market. The RSI is stabilising near the mid-zone, providing room for a fresh upside leg, while MACD is approaching levels where a potential bullish crossover on lower drawdown could emerge.SHYAMMETL (LTP: 973)View: BuyTarget: 1080SL: 930 Shyam Metalics is exhibiting a strong bullish breakout from a descending trendline on the weekly chart, indicating a potential resumption of the broader uptrend after a period of consolidation. Price has decisively moved above the 950-960 resistance zone, which also coincided with prior swing highs, adding conviction to the breakout.The structure reflects higher lows formation, suggesting steady accumulation. Momentum indicators are turning supportive with RSI trending upward above the mid-zone, while MACD has delivered a bullish crossover with rising histogram, reinforcing improving momentum. Weekly Supertrend breakout adds to positivity. Volume expansion near the breakout area further validates buyer participation and strengthens the breakout reliability. Additionally, price holding above short-term supports near 930 indicates a favorable risk-reward setup.As long as the stock sustains above the breakout zone, it is well-positioned to extend its upward move towards the 1080 target.

Nagpur woman raped, duped of Rs 14.8 lakh by man she met on matrimonial site

Nagpur woman raped, duped of Rs 14.8 lakh by man she met on matrimonial site

80 launch pads, 3 octagon installations: 'Alarming' Chinese buildup near nuke silos

According to images examined by Reuters, China has built more than 80 launch pads along with three large octagon-shaped facilities near the Hami nuclear missile silo field in the country's north-west. The launch pads could be used by mobile missile launchers and air-defence systems, while the larger facilities may support communications, electronic warfare and military command functions, according to security analysts who reviewed the imagery.

‘India a critical anchor’: US war secy Hegseth stresses Delhi must act in self-interest, points to China buildup

Praising India's defence manufacturing capabilities, Pete Hegseth said India could “support US Navy vessels” in future; he also spoke of joint manufacturing.

'Rightful alarm' over China military buildup: US

Molecule glue drugs shake up cancer care

One of the biggest advances in pancreatic cancer in decades came out of a crazy idea born in a Harvard University lab.Chemical biologist Gregory Verdine believed you could fight disease-causing proteins hidden inside cells by chemically gluing them to something else in the body and smothering them."Everybody told us this is crazy, that it would never work," he recalls.Revolution Medicines, which bought one of Verdine's companies in 2018, recently announced that one of its drugs doubled the typical survival time for patients with aggressive forms of the disease, from 6.7 months to 13.2 months. The full results from the company's final-stage trial are expected to be the star of the show at the annual confab of cancer doctors in Chicago this weekend.Spurred by the success of RevMed, numerous companies are now racing to develop similar drugs, dubbed "molecular glues", which can be used to treat a variety of ailments. And investors and pharmaceutical companies with deep pockets are chasing after them, creating one of the hottest corners of dealmaking in the industry.Also read | India's out-of-pocket healthcare spending drops significantly, govt data showsIt's not unusual for exciting new drugs to spark surges in stock prices and dealmaking frenzy. But molecular glue is a particularly complicated science, and the startups pursuing technologies similar to RevMed are mostly in early stages of testing. Their medicines won't be ready for years, if ever.That hasn't stopped big drugmakers such as Novartis, Roche Holding and Eli Lilly from inking research pacts with glue developers that could pay out billions of dollars in milestones.The boom has been especially lucrative for Monte Rosa Therapeutics. Over the past three years, the Boston-based biotech firm has signed three agreements that could be worth over $10 billion to develop molecular glue drugs with both Novartis and Roche.The company, which trades under the stock ticker GLUE, has seen its shares surge nearly 400% over the past year. It's preparing to start mid-stage trials for multiple drugs by the end of this year."The run-up in the share price is justified based on what we've seen so far," says Robert Driscoll, an analyst at Wedbush. Gains are "due to the success of their drugs rather than kind of exuberance around the glue technology as a whole", he says.Science of GlueMolecular glues work in a fundamentally different way from other oral medicines. Most pills - like Prozac for depression or Lipitor for cholesterol - are tiny chemicals that squeeze into a pocket inside a much larger protein to gum up its functioning. But many proteins have few obvious pockets, including key cancer-causing proteins.In fact, about 80% of all proteins in the body are what scientists refer to as "undruggable", meaning they can't be targeted with traditional drug technologies.RevMed's daraxonrasib cleverly circumvents this problem by acting as a molecular stickum. Once inside the body it binds to a healthy protein on one side and then draws in the bad protein to stick to the other side. The healthy protein helps block the bad protein and turn off its signalling.Competitors Line UpMultiple companies are chasing RevMed's lead in pancreatic cancer despite the long odds. San Diego-based Erasca is in early stages of testing a drug it says is more potent than daraxonrasib. Japanese drugmaker Astellas Pharma has begun final-stage trials of a degrader that may help a subset of pancreatic and lung cancer patients.Molecular glues are also being developed as alternatives to injectable drugs used to treat autoimmune and skin disorders. Shares of Kymera Therapeutics have soared more than 180% in the past year thanks to promising early trial results. The company is developing a once-daily pill it hopes will one day compete with Sanofi and Regeneron Pharmaceuticals' Dupixent, one of the world's bestselling drugs."The technology allows you to go after things that would have been almost impossible" to do previously with pills, says Nello Mainolfi, Kymera's founder and CEO.With few effective options for pancreatic cancer, analysts expect RevMed's daraxonrasib to become an enormous bestseller for the company.Prospects for daraxonrasib and speculation about a potential takeout deal have inflated RevMed's market cap to nearly $33 billion. That's a lofty figure for a drugmaker with no approved medicines.The company is preparing to file for US approval soon, and the FDA has promised to give the drug an ultrafast review. It's projected to reach $7 billion in sales a year by 2032, according to the average of estimates compiled by Bloomberg.

Sebi eases nomination rules for demat accounts, mutual funds. Check full details

Capital markets regulator Sebi has relaxed nomination norms for demat accounts and mutual fund folios, making the process simpler for investors while continuing its push to reduce the buildup of unclaimed financial assets.In a circular issued on Friday, the regulator said investors opening single-holder demat accounts or mutual fund folios after September 1, 2026, will be required to either nominate a beneficiary or formally opt out through a declaration.The move modifies rules introduced last year after market participants flagged operational challenges in implementing the earlier framework.Sebi said the revised norms are aimed at improving ease of investing and simplifying the nomination process.Under the new framework, nomination will remain mandatory for single-holder accounts unless the investor explicitly chooses to opt out. For jointly held accounts and folios, however, nomination will be optional.Investors will be allowed to appoint up to three nominees.In a significant simplification, Sebi has removed the requirement for a witness signature when investors submit nomination forms with a regular signature. A witness will now be required only when an investor uses a thumb impression instead of a signature.The regulator has also reduced the amount of information investors must provide while filing nominations.Only the nominee's name and relationship with the investor will be mandatory. In the case of minor nominees, the date of birth will also be required.Details such as mobile number, email address, percentage share, Aadhaar, PAN, passport or other identification documents will remain optional.Where multiple nominees are appointed but percentage allocation is not specified, the assets will be distributed equally among the nominees.Sebi has also expanded digital options for filing nominations. Investors will be able to submit nominations online using a digital signature certificate, Aadhaar-based e-sign, any recognised e-sign facility, or through two-factor authentication using a one-time password sent to their registered mobile number and email address.The regulator has directed depositories, depository participants, mutual fund registrars and asset management companies to provide both online and offline nomination facilities. The revised framework also allows investors to modify or cancel nominations any number of times.For jointly held accounts, all account holders must consent to any nomination or nomination change regardless of the mode of operation.Sebi has also introduced measures to encourage investors who have not provided nominations. Depository participants and mutual fund registrars will be required to send biannual SMS and email reminders to investors who have neither nominated a beneficiary nor formally opted out.In addition, online platforms will have to display pop-up messages highlighting the benefits of nomination whenever such investors log in to their accounts. The regulator said these nudges are intended to reduce the risk of securities and mutual fund units remaining unclaimed after the death of an investor.Sebi also wants greater transparency in account statements. Going forward, account and holding statements will either display the names of nominees or indicate whether a nomination exists, depending on the investor's preference.The market regulator has repeatedly expressed concerns over growing unclaimed financial assets and has been encouraging investors to update nominations across investment products.Under existing rules, securities that remain unclaimed for prolonged periods can eventually be transferred to the Investor Education and Protection Fund Authority (IEPF) under applicable regulations.Sebi said the revised norms supersede all previous circulars relating to nominations for demat accounts and mutual fund folios. The new framework will come into effect from September 1, 2026, giving market intermediaries time to upgrade their systems and implement the revised procedures.The changes are expected to make account opening and nomination management easier while ensuring smoother transmission of securities and mutual fund holdings to legal heirs and nominees.

Illegal call centre busted in Goa, 26 held for duping U.S. citizens

According to police, the accused targeted Americans by posing as officials of U.S.-based banks through internet-based calling systems

No Pending Challans? Andhra Father Gives Green Signal To Daughter’s Marriage

In Kakinada, Andhra Pradesh, a father asked Rayudupalem Traffic Police to check his prospective son-in-law’s challans, police found no violations and praised his approach

Fake Brides, Real Betrayal: 42 Families Duped In Madhya Pradesh Marriage Scam

The accused allegedly targeted families whose sons were struggling to find suitable brides

KTR talks of 24×7 drinking water supply in Hyderabad if voted to power

He asks party workers to be vigilant against enrolment of fake, duplicate votes by rival parties

Elderly man duped of ₹16.24 lakh in ‘digital arrest’ cyber fraud

Two held for allegedly duping elderly Bengaluru woman of ₹24 crore

(CBI). They allegedly told her that her bank accounts were linked to a money laundering case and warned her not to disclose the matter to anyone, claiming she was under “digital arrest.”